KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2021 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $52.3 million as the latest value for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $52.3 million; the TTM value through Dec 2025 reached $1.2 billion, up 213.48%, while the annual FY2025 figure was $1.2 billion, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $52.3 million in Q4 2025 for Alnylam Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.1 billion in Q3 2025 and bottomed at -$1.5 billion in Q4 2022.
  • Average Long-Term Debt Repayments over 3 years is $34.5 million, with a median of $276.2 million recorded in 2021.
  • On a YoY basis, Long-Term Debt Repayments climbed as much as 404.84% in 2022 and fell as far as 404.84% in 2022.
  • Alnylam Pharmaceuticals' Long-Term Debt Repayments stood at $500.0 million in 2021, then tumbled by 404.84% to -$1.5 billion in 2022, then surged by 103.43% to $52.3 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $52.3 million, $1.1 billion, and -$1.5 billion for Q4 2025, Q3 2025, and Q4 2022 respectively.